Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jemermed.2017.10.004 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Freedom from chronic lung allograft dysfunction (CLAD) or CLAD-free survival: What's in a name?
J Heart Lung Transplant
January 2019
Lung Transplantation Unit, University Hospital Gasthuisberg, Leuven, Belgium.
What's new in lung ultrasound in the critically ill or injured child.
Intensive Care Med
April 2019
Division of Pediatric Intensive Care and Neonatal Medicine, Paris South University Hospitals, 78 Rue du Général Leclerc, 94275, Le Kremlin-Bicêtre, France.
Bronchiolitis: What's All the Fuss About?
J Emerg Med
January 2018
Department of Emergency Medicine, University of California, San Francisco, San Francisco, CA.
Proceedings of the 3rd IPLeiria's International Health Congress : Leiria, Portugal. 6-7 May 2016.
BMC Health Serv Res
July 2016
Faculdade de Ciências do Desporto e Educação Física, Universidade de Coimbra, 3040-248 Coimbra, Portugal
Article Synopsis
- The text discusses various research studies focusing on health topics, including health literacy in adolescents and the impact of walking programs on individuals with schizophrenia.
- It also covers innovative medical practices, safety culture in patient care, and the psychological effects experienced by emergency crews after disasters.
- Additionally, it highlights issues such as musculoskeletal disorders in midwives, negative childhood experiences affecting adolescent mental health, and studies on vaccination timing and assessments in elderly care.
Immunosuppression: what's standard and what's new?
Semin Respir Crit Care Med
June 2013
Department of Medicine, Washington University School of Medicine, St. Louis, Missouri 63110, USA.
Lung transplantation is the ultimate treatment option for patients with end-stage lung disease. Chronic rejection, in the form of bronchiolitis obliterans syndrome, and noncytomegalovirus infections are the major causes of morbidity and mortality beyond the first year after transplantation. Most lung transplant recipients are treated lifelong with a three-drug immunosuppression regimen consisting of a calcineurin inhibitor, an antimetabolite, and low-dose corticosteroids.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!